Company Profile of CHENGHUI PHARMACEUTICAL GROUP LTD

Shandong Chenghui Pharmaceutical Group Co., Ltd. was founded in June 2002, with a registered capital of 130 million yuan, headquartered in Jinan, Shandong Province. It is a high-tech enterprise focusing on the research and development, production, sales and service of pharmaceutical APIs, intermediates and fine chemicals, and is committed to the research and development and application of new technologies in the fields of MAH, CDMO, veterinary medicine and agrochemicals, etc. The Group has one R&D center - Shandong Chengchuang Blue Ocean Pharmaceutical Technology Co. The group now has one R&D center-Shandong Chengchuang Blue Ocean Pharmaceutical Technology Co., Ltd, one API factory-Shandong Chenghui Shuangda Pharmaceutical Co., Ltd and two pharmaceutical intermediates production bases, with more than 1,000 employees, and more than 300 R&D team members. The products developed and manufactured by the company cover local anesthetics, antiviral drugs, cardiovascular and cerebrovascular drugs, antitumor drugs, digestive drugs, hypoglycemic drugs, veterinary drugs and other product categories. Especially in the "perioperative and antiviral" API research and production, is in a leading position, has formed a competitive advantage of the product structure, products are exported to more than 70 countries and regions around the world. The company's products Mildronate, Ropivacaine Hydrochloride and Articaine Hydrochloride have been submitted to CEP, of which Mildronate has obtained the CEP certificate; Vonorasan Fumarate, Proamphetamine Hydrochloride, Bupivacaine and Pramoxine Hydrochloride have been submitted to the FDA for the US-DMF documents and obtained the DMF file number; Sugar Glucose Sodium has been passed the audit and certification of MFDS in South Korea; and the Egyptian EDA of Vonorasan Fumarate has been approved and publicized; Domestic registrations have obtained 9 API file numbers for Lidocaine Hydrochloride, Pramoxine and Sugar Glucose Sodium.